3DNET
Drug Discovery and Development for Novel Eye Therapeutics
| Coordinatore | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Organization address
address: BELFIELD contact info |
| Nazionalità Coordinatore | Ireland [IE] |
| Totale costo | 1˙663˙674 € |
| EC contributo | 1˙663˙674 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2013-IAPP |
| Funding Scheme | MC-IAPP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-09-01 - 2017-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Organization address
address: BELFIELD contact info |
IE (DUBLIN) | coordinator | 717˙579.50 |
| 2 |
KALVISTA PHARMACEUTICALS LIMITED
Organization address
address: "Phi House, Enterprise road, Southampton Science Park" contact info |
UK (SOUTHAMPTON) | participant | 274˙693.75 |
| 3 |
RENASCI LIMITED
Organization address
address: PENNYFOOT STREET BIOCITY NOTTINGHAM contact info |
UK (NOTTINGHAM) | participant | 260˙997.44 |
| 4 |
UNIVERSIDAD DE VALLADOLID
Organization address
address: PLAZA SANTA CRUZ 8 PALACIO DE SANTA CRUZ contact info |
ES (VALLADOLID) | participant | 234˙967.12 |
| 5 |
GADEA BIOPHARMA SL
Organization address
address: "Parque Tecnologico de Leon, Edificio Usos" contact info |
ES (LEON) | participant | 175˙436.17 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Age-related macular degeneration, diabetic retinopathy, and corneal inflammation are significant causes of irreversible blindness with increasing prevalence as the EU population ages and the “diabetes epidemic” expands. There is an unmet clinical need for more effective treatments to halt or reverse these diseases. Many EU pharmaceutical and biotechnology companies, with established processes for the synthesis and physiochemical characterisation of drugs, have bespoke chemical libraries and lead drugs with potential to treat ocular disease, but lack the expertise and infrastructure to test these drugs in relevant pre-clinical models. In parallel, academic labs with excellent infrastructure to study ocular disease, lack the industry expertise to appropriately develop drugs to enter clinical trials. Thus, clinical development of ocular therapeutics is impeded in the EU due to poor collaboration among academic and industry scientists. 3D-NET establishes a network of industry (Gadea, KalVista & RenaSci) and academic partners (UCD & UVA), who exchange knowledge and people, and who’s combined S&T expertise will enhance the discovery and development of drugs that target ocular pathologies (retinal vessel permeability, unwanted blood vessel growth, inflammation and cell degeneration). Novel ophthalmic drugs will be discovered from unbiased screens of small molecules and developed from hits/leads and selected compounds (PI3K-inhs, lipoxins, Kallikrein-inhs, HDAC-inhs, serotonin agonists), on a set of in silico/in vitro/in vivo/ex vivo preclinical models. Expected outputs are: a) enhancing intersectoral training, career development and trans-national mobility of EU researchers, b) high impact publications/priority patent applications and c) overcoming barriers that impede industry-academia partnership in the EU inhibiting the discovery/development of new-cheaper and more effective drugs for ocular disease.'